SIONNA THERAPEUTICS, INC. Basic Shares Outstanding (Weighted Average)
SIONNA THERAPEUTICS, INC. (SION) reported Basic Shares Outstanding (Weighted Average) of 45.15 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 45.15M shares, a 2.34% increase year-over-year.
- SIONNA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 44.92M shares, a 68.90% increase year-over-year.
- SIONNA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 44.69M shares, a 851.34% increase year-over-year.
- SIONNA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 44.26M shares, a 886.56% increase year-over-year.
- SIONNA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 39.96M shares, a 935.60% increase from fiscal 2024.
- SIONNA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 3.86M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 45.15M shares 10-Q · filed 2026-08-06 | 45.31M shares 10-Q · filed 2026-08-06 | 44.92M shares derived: average of 3 quarters · filed 2026-08-06 | 44.75M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 44.92M shares 10-Q · filed 2026-05-12 | 44.80M shares derived: average of 2 quarters · filed 2026-05-12 | 44.62M shares derived: average of 3 quarters · filed 2026-05-12 | 44.50M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 44.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 44.47M shares derived: average of 2 quarters · filed 2026-03-02 | 44.35M shares derived: average of 3 quarters · filed 2026-08-06 | 39.96M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 44.26M shares 10-Q · filed 2025-11-05 | 44.19M shares derived: average of 2 quarters · filed 2026-08-06 | 38.39M shares 10-Q · filed 2025-11-05 | 29.92M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 44.12M shares 10-Q · filed 2026-08-06 | 35.40M shares 10-Q · filed 2026-08-06 | 25.14M shares derived: average of 3 quarters · filed 2026-08-06 | 19.97M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 26.60M shares 10-Q · filed 2026-05-12 | 15.65M shares derived: average of 2 quarters · filed 2026-05-12 | 11.93M shares derived: average of 3 quarters · filed 2026-05-12 | 9.73M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 4.70M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 4.59M shares derived: average of 2 quarters · filed 2026-03-02 | 4.11M shares derived: average of 3 quarters · filed 2026-03-02 | 3.86M shares 10-K · filed 2026-03-02 |
| 2024-09-30 | 4.49M shares 10-Q · filed 2025-11-05 | 3.82M shares derived: average of 2 quarters · filed 2025-11-05 | 3.58M shares 10-Q · filed 2025-11-05 | |
| 2024-06-30 | 3.16M shares 10-Q · filed 2025-08-11 | 3.12M shares 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | 3.08M shares 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |